David Lebowitz
Stock Analyst at Citigroup
(4.30)
# 410
Out of 5,139 analysts
119
Total ratings
59.77%
Success rate
14.38%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $76.33 | +10.05% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $62.58 | +34.23% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $25.65 | +87.13% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $16.79 | +19.12% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $205.83 | +40.89% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $106.21 | -3.02% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $33.92 | +12.03% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $38.94 | -43.50% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $76.26 | -12.14% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $43.96 | +27.39% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $12.50 | -20.00% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.29 | +16.28% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $72.48 | -37.91% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $91.05 | -25.32% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $501.68 | -23.86% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $54.59 | +75.86% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $4.58 | +162.01% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $359.27 | -54.35% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $25.85 | +50.87% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $20.52 | +2.34% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $6.31 | +6,318.38% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $4.50 | +211.11% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $76.33
Upside: +10.05%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $62.58
Upside: +34.23%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $25.65
Upside: +87.13%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $16.79
Upside: +19.12%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $205.83
Upside: +40.89%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $106.21
Upside: -3.02%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $33.92
Upside: +12.03%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $38.94
Upside: -43.50%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $76.26
Upside: -12.14%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $43.96
Upside: +27.39%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $12.50
Upside: -20.00%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.29
Upside: +16.28%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $72.48
Upside: -37.91%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $91.05
Upside: -25.32%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $501.68
Upside: -23.86%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $54.59
Upside: +75.86%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $4.58
Upside: +162.01%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $359.27
Upside: -54.35%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $25.85
Upside: +50.87%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $20.52
Upside: +2.34%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $6.31
Upside: +6,318.38%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $4.50
Upside: +211.11%